ClinicalTrials.gg
CompletedNCT06093945Updated Dec 5, 2023

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

A Phase 1 interventional study of SHR2554 tablet dosing and Omeprazole tablet dosing in Malignant Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study aimed to assess the effects of omeprazole on single-dose SHR2554 in healthy subjects, exploring the pharmacokinetic changes of SHR2554 and ensuring the safety when SHR2554 is co-administered with omeprazole.

02

Conditions studied

  • Malignant Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign an form before the trial and have a full understanding of the trial's content, procedures, and potential adverse reactions.
  2. Be able to complete the study according to the trial protocol.
  3. Healthy male and female subjects aged 18 to 45 (inclusive) on the day of signing the informed consent form.
  4. Female subjects of must use effective for 1 month from the date of signing the informed consent form until the last dose. Serum HCG testing before dosing must be negative. Male subjects with partners of childbearing potential must agree to use effective contraception measures and avoid sperm donation during the trial and for 1 month after the last administration of SHR2554.
  5. Male subjects must weigh at least 50 kg, and female subjects must weigh at least 45 kg, with a (BMI) ranging from 19 kg/m2 to 26 kg/m2 (inclusive).
  6. Health Condition: No history of heart, liver, kidney, gastrointestinal, neurological, psychiatric abnormalities, or metabolic disorders.
  7. Normal or clinically insignificant findings in vital signs, physical examination, routine laboratory tests (complete blood count, blood biochemistry, urinalysis, coagulation function, myocardial enzyme profile, thyroid function), echocardiography, posteroanterior chest X-ray, and abdominal ultrasound.
  8. Fridericia- interval (QTcF) of males should ≤ 430 ms, and ≤ 450 ms for females. (LVEF) should ≥ 50%.

Exclusion criteria

Exclusion Criteria:

  1. Positive results on screening tests for surface antigen, antibodies, syphilis spirochete antibodies, or antibodies.
  2. History of severe allergy/ or ongoing allergy/hypersensitivity, or history of hypersensitivity to SHR2554, its , or drugs with a similar chemical structure or class.
  3. Poorly controlled clinical heart symptoms or diseases such as: (1) Class 2 or higher heart failure; (2) Unstable angina; (3) Myocardial infarction within the past year; (4) Any supraventricular or ventricular arrhythmia requiring treatment or intervention.
  4. Occurrence of any of the following conditions within the past 6 months before screening: Myocardial infarction, severe/unstable angina, NYHA Class II-IV heart failure, continuous arrhythmias of ≥ Grade 2 (graded based on 5.0), heart failure, second or third-degree atrioventricular block, complete left bundle branch block, any grade of atrial fibrillation, coronary/peripheral artery bypass grafting or stent implantation, cerebrovascular accident (including ), pulmonary embolism, deep vein thrombosis.
  5. Use of any medication within the 4 weeks prior to the initial dose that carries a risk of prolonged /QTc interval or causing torsades de pointes (TdP) arrhythmia; a history of congenital QT interval prolongation syndrome or a family history of QT interval prolongation; presence of an implanted pacemaker or automated implantable cardioverter-defibrillator; uncorrected electrolyte disturbances, or any factors affecting QT/QTc studies.
  6. Pulmonary diseases, including infiltrative lung diseases, pneumonia, and respiratory distress.
  7. Chronic kidney disease, renal insufficiency, or a history of renal anemia.
  8. History of difficulty swallowing or any gastrointestinal disorders that affect drug absorption.
  9. Any uncontrolled digestive ulcers, colitis, pancreatitis, etc.
  10. Other primary diseases of important organs, such as neurological, cardiovascular, urological, digestive, respiratory, metabolic, and musculoskeletal system disorders, which makes the investigator believes it is unsuitable for participation in this study.
  11. Subjects who have undergone any surgery within 3 months prior to screening that could affect drug absorption, distribution, metabolism, or elimination.
  12. Subjects who have undergone any surgery within 6 months prior to screening.
  13. Subjects who have taken hepatotoxic drugs (such as acetaminophen, erythromycin, fluconazole, ketoconazole, rifampin, etc.) within 6 months prior to screening.
  14. Subjects who have participated in a clinical trial within 3 months prior to screening.
  15. Subjects who have taken known or CYP2C19 inducers/inhibitors (see Appendices 2 and 3) within 28 days prior to the first administration of SHR2554.
  16. Subjects who have taken any prescription or non-prescription medications within 7 days prior to the first administration of SHR2554.
  17. Subjects who have consumed any vitamin products or herbal supplements within 7 days prior to the first administration of SHR2554.
  18. Subjects who abuse alcohol or excessive intake of alcohol within 6 months prior to screening, defined as consuming more than 14 units of alcohol per week (1 unit = 285 mL of beer, 25 mL of 40% alcohol, or 100 mL of wine); or subjects with an alcohol breath test result ≥20 mg/dL during screening.
  19. Subjects who have smoked more than 5 cigarettes per day or habitually use nicotine-containing products within 3 months prior to screening, and are unable to quit during the study or have a positive nicotine screening result during screening.
  20. Subjects who misuse drugs or have used recreational drugs (such as cannabis) within 3 months prior to screening, or have used hard drugs (such as cocaine, amphetamines, ecstasy, etc.) within the past year, or have a positive result on drug abuse (substance abuse) screening during screening.
  21. Subjects who have consumed grapefruit or grapefruit-containing products, caffeine, xanthine, or alcohol-containing foods or beverages within 48 hours prior to the first administration of SHR2554; engaged in strenuous exercise, or have other factors that may affect drug absorption, distribution, metabolism, or excretion.
  22. Subjects who habitually consume grapefruit juice or excessive amounts of tea, coffee, and/or caffeinated beverages, and are unable to abstain during the study.
  23. Subjects who donated blood within the last 3 months and donated ≥400 mL of blood or experienced blood loss ≥400 mL, donated blood within the last 1 month and donated ≥200 mL of blood or experienced blood loss ≥200 mL, or received a blood transfusion.
  24. Subjects with a history of syncope or vasovagal episodes, difficulty with blood collection, or an inability to tolerate venipuncture.
  25. Subjects who, in the opinion of the investigator, have other factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    SHR2554 and omeprazole

    Sequential treatments of SHR2554 alone followed by SHR2554+ omeprazole, with a washout period in between.

    Drug: SHR2554 tablet dosing · Drug: Omeprazole tablet dosing

Interventions

  • SHR2554 350mg taken on Day 1 and Day 10

  • DrugOmeprazole tablet dosing

    Omeprazole taken from Days 5 to Day 10

06

What researchers measure

Primary outcomes

  1. Cmax of SHR2554: Rate and extent of absorption of SHR2554 following single oral doses of SHR2554 by assessment of maximum plasma concentration.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  2. AUC0-t of SHR2554: Assessment of the PK of SHR2554 using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  3. AUC0-∞ of SHR2554: Assessment of the PK of SHR2554 using area under the plasma concentration-time curve from zero to infinity.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  4. Tmax of SHR2554: Assessment of the PK of SHR2554 using time to reach maximum plasma concentration.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  5. t1/2 of SHR2554: Assessment of the PK of SHR2554 using the terminal half-life.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  6. CL/F of SHR2554: Assessment of the PK of SHR2554 using the apparent plasma clearance.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

  7. Vz/F of SHR2554: Assessment of the PK of AZD9291 using the apparent volume of distribution.

    Time frame: PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose

Secondary outcomes

  1. Incidence and severity of adverse events/serious adverse events

    Time frame: From Day 1 to Day 15

  2. Change in Fridericia-corrected QTc interval (QTcF) relative to baseline (ΔQTcF)

    Time frame: ECG samples collected in period 1 at pre-dose,1, 2, 3, 4, 6, 8, 12, and 24 hours post SHR2554 dose

07

Study locations

1 site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 318000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2023, 0 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 0 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartActual
Nov 6, 2023
Primary completionActual
Nov 29, 2023
CompletionActual
Nov 29, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06093945
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 6, 2023
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Last update
Dec 5, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion